SCHEMBL170586

SCHEMBL170586

C=CCNN(CC=C)CC=C

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28784380 0.97 SMN1; SMN2 (0.31) SMN1; SMN2
SCHEMBL20440769 0.79 CYP1A2 (0.30)
SCHEMBL2364576 0.79 FAAH (0.39)
SCHEMBL3674964 0.77
SCHEMBL16654852 0.77
SCHEMBL1685448 0.74 TSHR (0.30)
SCHEMBL8656915 0.72
SCHEMBL17226154 0.72
SCHEMBL11617998 0.72 TSHR (0.35)
SCHEMBL11134053 0.72 ALDH1A1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023230217-A1 ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2023-11-30 WO claimed
US-20230381142-A1 ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2023-11-30 US claimed
CN-112334468-A Quinoline compounds, their preparation and use as antimalarial agents 美国卫生和人力服务部 2021-02-05 CN claimed
US-20170355695-A1 SMYD Inhibitors Epizyme, Inc. (US) 2017-12-14 US claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20130317028-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2013-11-28 US claimed
EP-2308874-B1 Bridged monobactams useful as beta-lactamase inhibitors BASILEA PHARMACEUTICA AG (CH) 2013-01-23 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
EP-2027086-B1 N-BENZOYL-PYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS WYETH LLC (US) 2011-11-16 EP claimed
WO-1986003749-A1 BICYCLIC HETEROARYL THIAZOLE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES RORER INTERNATIONAL (OVERSEAS) INC. (US) 1986-07-03 WO claimed
US-4529602-A Sulfodehydroabietic acid compound TANABE SEIYAKU CO., LTD. (JP) 1985-07-16 US claimed
EP-0066241-B1 MODIFIED CIS-1,4-POLYISOPRENE RUBBER, A PROCESS FOR ITS MANUFACTURE, A VULCANIZED MODIFIED CIS-1,4-POLYISOPRENE RUBBER COMPOSITION AND THE USE OF THE MODIFIED CIS-1,4-POLYISOPRENE RUBBER FOR PREPARING VULCANIZED SHAPED ARTICLES KURARAY CO., LTD. (JP) 1985-05-08 EP claimed
EP-0119050-A2 Dihydropyridine anti-ischaemic and antihypertensive agents Pfizer Limited (GB) 1984-09-19 EP claimed
US-4446281-A Modified cis-1,4-polyisoprene rubber, a process for manufacturing the same, and a composition containing the same KURARAY CO., LTD. (JP) 1984-05-01 US claimed
EP-0066241-A2 Modified cis-1,4-polyisoprene rubber, a process for its manufacture, a vulcanized modified cis-1,4-polyisoprene rubber composition and the use of the modified cis-1,4-polyisoprene rubber for preparing vulcanized shaped articles KURARAY CO., LTD. (JP) 1982-12-08 EP claimed
EP-0013727-B1 PREPARATION OF (THIO)HYDANTOINS AND THEIR APPLICATION AS HEAT-RESISTANT COATINGS, FILMS, POWDERS, ADHESIVES, MOULDED PRODUCTS, LACQUERS AND FIBRES BAYER AG (DE) 1982-04-07 EP claimed
EP-0016565-A1 1,2,4-Triazole derivatives, processes for their production and pharmaceutical compositions containing them GLAXO GROUP LIMITED (GB) 1980-10-01 EP claimed
US-4225588-A POLYCYCLIC NITROGEN-CONTAINING COMPOUNDS AS POTENTIATORS FOR BLEOMYCINS OR PHLEOMYCINS COMMONWEALTH SCIENTIFIC & INDUSTRIAL RESEARCH ORGANIZATION (AU) 1980-09-30 US claimed
EP-0005782-A1 Plant growth regulants and compositions containing them, their application and their preparation BAYER AG (DE) 1979-12-12 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230381142-A1 ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF MPO, SSB, SGMS2 SMN1; SMN2 4698/4885
US-20130317028-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 SMN1; SMN2 2376/4885
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD SMN1; SMN2 3999/4885
US-20170355695-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 SMN1; SMN2 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.